Coronavirus / COVID

Adults with type 2 diabetes who use metformin have a 13% to 21% reduced risk of developing Long COVID or dying from COVID-19 compared to those taking other diabetes medications.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

Females are more frequently affected by Long COVID than males, highlighting distinct immunological processes and hormonal variations.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.

As National Immunization Awareness Month concludes this August, it is a good time to review and update your vaccination schedules before the fall season begins.

Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.

The 2024-2025 season introduces a new vaccine formula with a monovalent component designed to enhance protection against current variants and reduce severe outcomes such as hospitalization and death.

The NIH’s RECOVER Initiative has developed new symptom indices for Long COVID in school-age children and adolescents to find 14 symptoms overlapping between the two groups.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

Study highlights that many long-term symptoms may result from ongoing inflammation rather than persistent viral presence.

A new phase 1 clinical trial will determine if vaccine candidate, MPV/S-2P, is safe for humans, and may potentially offer protection not seen before in the first-generation of COVID-19 vaccines.

A large English study shows the incidence rates of arterial thromboses and venous thrombotic events decreased after immunization.

New funding will go towards research around a specific molecule that has been shown to lower inflammation.

A new study looks at the role of genetics in the leveling degrees of infection.

A new analysis says if all states imposed such measures it would have saved thousands of lives.

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

Evaluating nirmatrelvir–ritonavir over 5-10 days for post-exposure prophylaxis revealed no reduction in symptomatic SARS-CoV-2 infections compared to placebo among asymptomatic adults.

A large study from the Veterans Affairs shows an association between being unvaccinated and a greater incidence rate of Long COVID.

The disconnect between evolving science and medical communication has left people confused about how to interpret public health information, and provided an opportunity for vaccine deniers and politicians to give disinformation on COVID-19.

Emily Hadley highlights study findings showing a higher incidence of Long COVID following initial infections compared to reinfections, particularly during the Omicron period among 3 million patients.

The company acquired rights from CureVac to develop vaccines for influenza and COVID-19 using the mRNA platform.